Published Date: 08 Mar 2023
The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).
Read Full NewsResearchers seek to understand why Asian women fare better with the disease.
By carefully controlling the mix of stem and T cells, Orca‑T lowers the risk for graft-vs-host disease in adults with hematologic cancers.
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation